Fifth Third Wealth Advisors LLC Makes New $217,000 Investment in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Fifth Third Wealth Advisors LLC purchased a new position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) during the 1st quarter, Holdings Channel reports. The institutional investor purchased 225 shares of the biopharmaceutical company’s stock, valued at approximately $217,000.

Several other institutional investors and hedge funds have also bought and sold shares of the company. West Paces Advisors Inc. grew its holdings in shares of Regeneron Pharmaceuticals by 575.0% during the first quarter. West Paces Advisors Inc. now owns 27 shares of the biopharmaceutical company’s stock valued at $26,000 after buying an additional 23 shares during the last quarter. Fortitude Family Office LLC purchased a new stake in shares of Regeneron Pharmaceuticals during the fourth quarter valued at $31,000. MCF Advisors LLC grew its holdings in shares of Regeneron Pharmaceuticals by 50.0% during the fourth quarter. MCF Advisors LLC now owns 36 shares of the biopharmaceutical company’s stock valued at $32,000 after buying an additional 12 shares during the last quarter. Criterion Capital Advisors LLC purchased a new stake in shares of Regeneron Pharmaceuticals during the fourth quarter valued at $37,000. Finally, Bruce G. Allen Investments LLC purchased a new stake in shares of Regeneron Pharmaceuticals during the fourth quarter valued at $40,000. 83.31% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling

In related news, Director Bonnie L. Bassler sold 756 shares of the business’s stock in a transaction that occurred on Monday, June 24th. The stock was sold at an average price of $1,062.00, for a total transaction of $802,872.00. Following the completion of the sale, the director now owns 1,382 shares in the company, valued at $1,467,684. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. In other Regeneron Pharmaceuticals news, Director Bonnie L. Bassler sold 756 shares of the business’s stock in a transaction that occurred on Monday, June 24th. The stock was sold at an average price of $1,062.00, for a total value of $802,872.00. Following the completion of the sale, the director now owns 1,382 shares in the company, valued at $1,467,684. The sale was disclosed in a document filed with the SEC, which is available through this link. Also, CEO Leonard S. Schleifer sold 22,830 shares of the business’s stock in a transaction that occurred on Friday, May 17th. The shares were sold at an average price of $979.23, for a total value of $22,355,820.90. Following the completion of the sale, the chief executive officer now owns 466,877 shares of the company’s stock, valued at approximately $457,179,964.71. The disclosure for this sale can be found here. Insiders sold a total of 61,971 shares of company stock worth $61,217,654 over the last 90 days. 7.48% of the stock is owned by insiders.

Regeneron Pharmaceuticals Stock Up 0.0 %

Shares of Regeneron Pharmaceuticals stock traded up $0.17 on Friday, reaching $1,051.03. 737,058 shares of the company were exchanged, compared to its average volume of 480,121. Regeneron Pharmaceuticals, Inc. has a 1-year low of $688.52 and a 1-year high of $1,081.17. The company has a market cap of $115.81 billion, a P/E ratio of 31.04, a price-to-earnings-growth ratio of 2.21 and a beta of 0.13. The company has a debt-to-equity ratio of 0.10, a current ratio of 5.27 and a quick ratio of 4.51. The stock’s 50 day moving average price is $978.05 and its 200-day moving average price is $948.28.

Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its earnings results on Thursday, May 2nd. The biopharmaceutical company reported $7.97 earnings per share for the quarter, missing the consensus estimate of $8.46 by ($0.49). The business had revenue of $3.15 billion for the quarter, compared to analysts’ expectations of $3.19 billion. Regeneron Pharmaceuticals had a return on equity of 16.83% and a net margin of 29.45%. As a group, equities analysts forecast that Regeneron Pharmaceuticals, Inc. will post 37.23 EPS for the current year.

Analyst Upgrades and Downgrades

A number of research analysts recently issued reports on the stock. Sanford C. Bernstein assumed coverage on shares of Regeneron Pharmaceuticals in a research report on Tuesday, March 12th. They set an “outperform” rating and a $1,125.00 target price for the company. Evercore ISI assumed coverage on shares of Regeneron Pharmaceuticals in a research report on Tuesday, May 14th. They set an “outperform” rating and a $1,150.00 target price for the company. JPMorgan Chase & Co. boosted their target price on shares of Regeneron Pharmaceuticals from $1,050.00 to $1,150.00 and gave the company an “overweight” rating in a research report on Monday, June 17th. Morgan Stanley boosted their price objective on Regeneron Pharmaceuticals from $1,104.00 to $1,115.00 and gave the company an “overweight” rating in a research report on Wednesday, March 13th. Finally, TD Cowen boosted their price target on Regeneron Pharmaceuticals from $1,020.00 to $1,030.00 and gave the stock a “buy” rating in a research report on Wednesday, April 24th. One research analyst has rated the stock with a sell rating, four have given a hold rating, seventeen have assigned a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $1,015.91.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.